Anti-DFS70 antibodies detected by specific methods in patients with thrombosis or recurrent pregnancy loss: no evidence of an association.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 05 2020
08 05 2020
Historique:
received:
06
12
2019
accepted:
17
04
2020
entrez:
10
5
2020
pubmed:
10
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
A dense fine speckled pattern (DFS) caused by antibodies to the DFS70 kDa nuclear protein is a relatively common finding while testing for anti-nuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells. However, despite many efforts and numerous studies, the clinical significance of anti-DFS70 antibodies is still unknown as they can be found in patients with various disorders and even in healthy subjects. In this study we aimed at verifying whether these antibodies are associated with thrombotic events or with unexplained recurrent pregnancy loss (RPL). We studied 443 patients with venous or arterial thrombosis or RPL and 244 controls by IIF on HEp-2 cells and by a DFS70-specific chemiluminescent immunoassay (CIA). The DFS pattern was observed in IIF in 31/443 (7.0%) patients and in 6/244 (2.5%) controls (p = 0.01) while anti-DFS70 specific antibodies were detected by CIA in 11 (2.5%) patients and in one (0.4%) control (p = 0.06). Positive samples, either by IIF or by CIA, were then assayed by a second DFS70-specific line-immunoassay (LIA) method: 83.3% of the CIA positive samples were confirmed DFS70 positive versus only 29.7% of the IIF positive samples. These findings show that IIF overestimates anti-DFS70 antibody frequency and that results obtained by specific CIA and LIA assays do not indicate that venous or arterial thrombosis or RPL are linked to a higher prevalence of anti-DFS70 antibodies.
Identifiants
pubmed: 32385308
doi: 10.1038/s41598-020-64550-y
pii: 10.1038/s41598-020-64550-y
pmc: PMC7210276
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Autoantibodies
0
PSIP1 protein, human
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7748Références
Singh, D. P., Ohguro, N., Chylack, L. T. Jr & Shinoara, T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Invest. Ophtalmol. Visual Sci. 40, 1444–51 (1999).
Shinohara, T., Singh, D. P. & Fatma, N. LEDGF, a survival factor, activates stress-related genes. Prog. Retin. Eye Res. 21, 341–358 (2002).
doi: 10.1016/S1350-9462(02)00007-1
Ganapathy, V., Daniels, T. & Casiano, C. A. LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. Autoimmun. Rev. 2, 290–297 (2003).
doi: 10.1016/S1568-9972(03)00063-6
Ganapathy, V. & Casiano, C. A. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum. 50, 684–688 (2004).
doi: 10.1002/art.20095
Ochs, R. L. et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin. Exp. Med. 16, 273–293 (2016).
doi: 10.1007/s10238-015-0367-0
Conrad, K., Röber, N., Andrade, L. E. C. & Mahler, M. The clinical relevance of anti-DFS70 antibodies. Clin. Rev. Allerg. Immunol. 52, 202–216 (2017).
doi: 10.1007/s12016-016-8564-5
Carbone, T. et al. Prevalence and serological profile of anti-DFS70 positive subjects from a routine ANA cohort. Sci. Rep. 9, 2177 (2019).
doi: 10.1038/s41598-019-38686-5
Dellavance, A. et al. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J. Rheumatol. 32, 2144–2149 (2005).
pubmed: 16265692
Bizzaro, N. et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann. N.Y. Acad. Sci. 1107, 174–183 (2007).
doi: 10.1196/annals.1381.019
Mahler, M. et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 39, 2104–2110 (2012).
doi: 10.3899/jrheum.120598
Fabris, M. et al. Anti-DFS70 antibodies: a useful biomarker in a pediatric case with suspected autoimmune disease. Pediatrics 134, e1706–1708 (2014).
doi: 10.1542/peds.2013-3914
Infantino, M. et al. The clinical impact of anti-DFS70 antibodies in undifferentiated connective tissue disease: case reports and a review of the literature. Immunol. Res. 65, 293–295 (2017).
doi: 10.1007/s12026-016-8836-4
Vazquéz-Del Mercado, M. V. et al. Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms. Autoimmun. Highlights 8, 1, https://doi.org/10.1007/s13317-016-0089-7 (2017).
doi: 10.1007/s13317-016-0089-7
Watanabe, A. et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 503, 892–900 (2004).
doi: 10.1002/art.20096
Mariz, H. A. et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 63, 191–200 (2011).
doi: 10.1002/art.30084
Muro, Y., Sugiura, K., Morita, Y. & Tomita, Y. High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 17, 171–176 (2008).
doi: 10.1177/0961203307086311
Bizzaro, N., Tonutti, E. & Villalta, D. Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEp-2 cells: Not an easy task! Arthritis Rheum. 63, 4036–4037 (2011).
doi: 10.1002/art.30621
Bentow, C., Fritzler, M. J., Mummert, E. & Mahler, M. Recognition of the dense fine speckled (DFS) pattern remains challenging: Results from an international internet based survey. Autoimmun. Highlights 7, 8, https://doi.org/10.1007/s13317-016-0081-2 (2016).
doi: 10.1007/s13317-016-0081-2
Bizzaro, N. et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computer-aided diagnostic systems. Autoimmun. Rev. 13, 292–298 (2013).
doi: 10.1016/j.autrev.2013.10.015
Mahler, M. & Fritzler, M. J. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin. Dev. Immunol. 2012, 494356 (2012).
doi: 10.1155/2012/494356
Bizzaro, N. et al. Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence. Clin. Chim. Acta 451, 271–277 (2015).
doi: 10.1016/j.cca.2015.10.008
Bizzaro, N. et al. Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. J. Immunol. Methods 436, 50–53 (2016).
doi: 10.1016/j.jim.2016.06.008
Bentow, C. et al. Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. Lupus 25, 897–904 (2016).
doi: 10.1177/0961203316641773
Malyavantham, K. & Suresh, L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Autoimmun. Highlights 8, 3 (2017).
doi: 10.1007/s13317-017-0091-8
Bizzaro, N. & Fabris, M. New genetically engineered DFS70 knock-out HEp-2 cells enable rapid and specific recognition of anti-DFS70 antibodies. Autoimmunity 51, 152–156 (2018).
doi: 10.1080/08916934.2018.1469013
Marlet, J. et al. Thrombophilia associated with anti-DFS70 autoantibodies. PLoS ONE 10, e0138671 (2015).
doi: 10.1371/journal.pone.0138671
Mahler, M. et al. Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. Autoimmun. Rev. 15, 198–201 (2016).
doi: 10.1016/j.autrev.2015.11.006
Fatma, N., Singh, D. P., Shinoara, T. & Chylack, L. T. Jr Heparin’s role in stabilizing, potentiating, and transporting LEDGF into the nucleus. Invest. Ophtalmol. Vis. Sci. 41, 2648–2657 (2000).
ESHRE Guideline Group on RPL, et al. ESHRE Guideline: Recurrent Pregnancy Loss. Hum. Reprod. Open 2. https://doi.org/10.1093/hropen/hoy004 (2018).
Basu, A., Sanchez, T. W. & Casiano, C. A. DFS70/LEDGFp75: An enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front. Immunol. 6, 116 (2015).
doi: 10.3389/fimmu.2015.00116
Basu, A. et al. Specificity of antinuclear autoantibodies recognizing the dense fine speckled nuclear pattern: Preferential targeting of DFS70/LEDGFp75 over its interacting partner MeCP2. Clin. Immunol. 161, 241–250 (2015).
doi: 10.1016/j.clim.2015.07.014
Ortiz-Hernandez, G. L., Sanchez-Hernandez, E. S. & Casiano, C. A. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions. Auto Immun. Highlights 11, 3 (2020).
doi: 10.1186/s13317-020-0126-4
Mahler, M., Andrade, L. E., Casiano, C. A., Malyavantham, K. & Fritzler, M. J. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev. Clin. Immunol. 15, 241–250 (2019).
doi: 10.1080/1744666X.2019.1562903
Bonroy, C. et al. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin. Chem. Lab. Med. 56, 1090–1099 (2018).
doi: 10.1515/cclm-2017-0541
Albesa, R. et al. Increased prevalence of anti-DFS70 antibodies in young females: experience from large international multi-center study on blood donors. Clin. Chem. Lab. Med. 57, 999–1005 (2019).
doi: 10.1515/cclm-2018-1233
Choi, M. Y. et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 26, 1051–1059 (2017).
doi: 10.1177/0961203317692437